Neoplasm Metastasis Clinical Trial
Official title:
To Determine Which of Two Radiotherapy Brain Fractionation Schemes is Superior in the Treatment of Brain Metastases
This is a comparison of radiotherapy fractionation schemes for brain metastasis.
Untreated brain metastases are usually fatal within a few weeks. The standard treatment for
brain metastases is whole brain irradiation. This results on average in an increase in
survival by 2 to 4 times compared to withholding irradiation. The majority of patients
experience improvement in the level of functioning as a result of irradiation. None-the-less
approximately half of patients die because of progression of the brain metastases and their
quality of life is often dominated by the effects of brain metastases.
Various different dosages of radiation have been assessed and we wish to further investigate
this by comparing a less intense schema with a more intense schema. Both of these fall
within the range of published experience but have not been directly compared. The more
intense schema may have more effect on the tumour but previous variations of dose intensity
have not shown significant differences in survival. Differences in control of the metastases
in the brain have been suggested but there have been no good comparisons of quality of life.
Obviously when survival is measured on average in only 3 to 6 months, this is an important
parameter for comparison.
Comparisons: Stratification is by diagnosis either excision or biopsy/clinical. Patients
will be randomised to receive either 40Gy 20#bd or 20Gy 4#daily.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03775980 -
CIRSE Emprint Microwave Ablation Registry
|
||
| Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
| Terminated |
NCT03986593 -
Cryoablation of Bone Metastases From Endocrine Tumors
|
N/A | |
| Active, not recruiting |
NCT04458259 -
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
|
Phase 1 | |
| Completed |
NCT01218542 -
Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
|
N/A | |
| Not yet recruiting |
NCT03175146 -
A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely
|
N/A | |
| Active, not recruiting |
NCT02395224 -
A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
|
||
| Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
| Recruiting |
NCT01960829 -
Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study
|
Phase 2 | |
| Terminated |
NCT01846429 -
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
|
Phase 1 | |
| Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
| Recruiting |
NCT01564810 -
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
|
Phase 4 | |
| Completed |
NCT00375245 -
Rapamycin With Grapefruit Juice for Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00232726 -
Clinical Study of Previously Untreated Patients With Malignant Melanoma
|
Phase 2 | |
| Completed |
NCT00207116 -
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
|
Phase 1 | |
| Completed |
NCT00207103 -
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT00172003 -
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
|
Phase 4 |